Perazodin

Quick links to important sections

Perazodin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perazodin

Quick Facts: Perazodin (Dipyridamole)

Property Description
Active ingredient Dipyridamole
Form Tablets, Dragees, Solution for injection
Pharmacological class Antiplatelet agent (Platelet aggregation inhibitor)
General purpose Prophylaxis against blood clot formation
Origin Synthetic compound (Pyrimido-pyrimidine derivative)

What Type of Medicine is Perazodin (Dipyridamole)?

Perazodin is a pharmaceutical entity defined by the presence of a single active ingredient, Dipyridamole, which classifies it as an antiplatelet agent. This classification signifies its action in inhibiting the clumping of blood platelets. The active substance is a synthetic compound chemically characterized as a pyrimido-pyrimidine derivative. The compound's antiplatelet action is utilized in preventative cardiovascular regimens.

Composition and Physical Forms of Perazodin

The medicine is supplied as a single-ingredient product, containing only Dipyridamole along with necessary pharmaceutical excipients. Perazodin is available for administration via both the oral and intravenous routes. The dosage forms include solid forms such as tablets and dragees, and an aqueous solution for injection, which offers flexibility for various clinical needs. The availability of both oral and intravenous presentations differentiates this drug profile, allowing for tailored application.

General Purpose and Anti-Thrombotic Action

The general purpose of Perazodin is to act as a prophylactic agent to aid in the maintenance of smooth blood flow. Dipyridamole achieves this high-level benefit by preventing platelets from clumping and by acting as a vasodilator, or blood vessel opener. This combination of effects—preventing clot formation and promoting blood vessel dilation—is central to its utility in helping to reduce the risk associated with potential blood clot formation in the circulatory system.

Regulatory References

  1. Dipyridamole - StatPearls - NCBI

What side effects are possible with Perazodin?

Possible Side Effects and Safety Information: Perazodin (Dipyridamole)

The officially documented safety profile of Perazodin, based on regulatory labeling, classifies adverse reactions by frequency and affected physiological system. The most frequently expected side effects are generally classified as Very Common or Common and are often noted to be transient.

Frequency-Classified Adverse Reactions

The most commonly reported events are categorized as:

Classification Examples of Documented Reactions
Very Common (ge 10%) Headache, Dizziness, Dyspepsia, Diarrhea, Nausea, Gastric pain.
Common (1% to <10%) Flushing, Vomiting, Rash, Angina pectoris.

These reactions primarily involve the Nervous System Disorders and Gastrointestinal Disorders categories. Regulatory documents note that these initial side effects may disappear with long-term use of the medication.

Serious Adverse Reactions and Safety Constraints

The label explicitly documents rare but clinically significant adverse reactions, including Myocardial Infarction (fatal and non-fatal), Stroke, and Severe Anaphylactoid Reactions. These are primarily associated with the intravenous form used in diagnostic procedures.

Safety constraints advise caution for use in patients with certain conditions. Specifically, Dipyridamole should be used with caution in individuals with pre-existing severe coronary artery disease and in those with Hepatic Insufficiency. Furthermore, due to its properties, the medicine requires caution in patients at an increased bleeding risk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe specific clinical manifestations that may occur following an overdose of Perazodin (Dipyridamole). Overdosage may present with symptoms related to the drug's hemodynamic effects, including a warm feeling, flushes, sweating, restlessness, dizziness, and a feeling of weakness. More serious presentations involve distinct cardiovascular changes, documented as a significant drop in blood pressure (hypotension) and tachycardia (rapid heart rate).

Immediate Emergency Actions

In the event of a real or suspected overdose, regulatory guidance strictly mandates that immediate action must be taken: seek medical attention and contact a Poison Control Center immediately. Careful medical management is essential, and hospital observation may be required.

Supportive Care and Management

The regulatory profile outlines specific supportive measures. These include recommendations for symptomatic treatment and consideration of a vasopressor drug to manage severe hypotension. Gastric lavage may also be considered as part of the initial management. While no specific conventional antidote is listed, aminophylline, a xanthine derivative, is documented as an agent that may reverse the drug’s hemodynamic effects. Due to the high protein binding of Dipyridamole, dialysis is not anticipated to be of benefit in the management of overdose.

Therapeutic Uses of Perazodin

What Perazodin Treats: Main Uses and Benefits

Perazodin (Dipyridamole) is generally used for its prophylactic (preventative) benefits against blood vessel blockages and is applied across three relevant high-risk clinical domains. Its application is intended to help lessen the chance of serious medical problems that occur when a blood vessel is blocked by clots.

The primary uses of Perazodin include managing the risk of thrombotic complications following mechanical heart valve replacement, serving as a long-term strategy for the secondary prevention of cerebrovascular events (like stroke or TIA), and its specialized use in cardiac diagnostic testing for assessing coronary artery disease.

“Perazodin is commonly used in clinical scenarios where the maintenance of smooth, stable blood flow is a critical, high-risk, chronic therapeutic goal.”


Reducing the Risk of Thrombotic Complications

Perazodin is commonly used for patients at high chronic risk of blood clots forming in their circulation, such as individuals who have received a mechanical heart valve replacement. This is considered relevant as an adjunctive agent that supports the maintenance of smooth blood flow and may contribute to easing the risk of a serious or highly disruptive blockage. The medication is intended to support the physiological maintenance of clear pathways to reduce the risk of potential vascular obstruction.


Quick Fact: Vascular Blockage Risk Management Perazodin is relevant for assisting with maintaining functional stability in high-risk cardiovascular patients by supporting consistent circulatory flow.

Secondary Prevention of Cerebrovascular Events

The medication is employed as a long-term strategy to decrease the chance of a recurrent vascular event in patients who have a history of ischemic stroke or a transient ischemic attack (TIA). It helps address the physiological factors associated with underlying cerebrovascular risk, supports the maintenance of stable blood flow to the brain, and may assist with managing the risk of recurrent vascular events.

Specialized Use in Cardiac Diagnostic Testing

A unique, non-preventative use of intravenous Perazodin is its application in specialized cardiac stress testing during myocardial perfusion imaging. This is a relevant tool for physicians to help assess coronary artery disease (CAD) and evaluate blood flow to the heart in patients who are physically unable to perform a standard exercise test.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Perazodin (dipyridamole) is a medication used in certain adult patients, often in combination with an anticoagulant or antiplatelet agent, to prevent blood clots associated with heart valve replacement or other circulatory issues. Like all prescription medications, it is not suitable for everyone and requires careful evaluation by a healthcare provider.

Who Cannot Use Perazodin?

Contraindications (Avoid Use):

  • Allergy or Hypersensitivity: Patients with a known allergy to dipyridamole or any of the product's inactive ingredients should not take this medicine.
  • Children: The tablets are generally not recommended for use in children under 12 years of age.

When to Use with Caution

Use of Perazodin may require dose adjustment or close monitoring in individuals with certain existing conditions. It is crucial to inform your doctor if you have or have had any of the following:

Condition
Severe Coronary Artery Disease: Including unstable angina or a recent myocardial infarction (heart attack).
Bleeding/Coagulation Disorders: Due to the risk of increased bleeding.
Myasthenia Gravis: An autoimmune neuromuscular disease, as it may worsen symptoms.
Hypotension (Low Blood Pressure): As Perazodin can cause peripheral vasodilation.
Severe Liver Problems: As it may affect drug processing.
Pregnancy/Breastfeeding: Use during these periods should only be considered if the physician deems it essential and the benefits outweigh the potential risks.

Additionally, patients taking certain medications, such as some other antiplatelet drugs, anticoagulants, or high-dose non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief, may have an increased risk of bleeding. The use of Perazodin may also interfere with certain types of cardiac stress testing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Perazodin’s official interaction profile is characterized by significant pharmacodynamic interactions and specific procedural restrictions documented in regulatory prescribing information. Co-administration with Riociguat is contraindicated due to the severe risk of additive hypotension. Similarly, Methylxanthines, such as Theophylline, are prohibited before and during diagnostic stress testing because they antagonize Dipyridamole's essential vasodilatory effect.

Pharmacodynamic and Procedural Restrictions

Co-administration with Anticoagulants, NSAIDs, and other Antiplatelet Agents increases the risk and severity of bleeding or hemorrhage due to additive effects on hemostasis. The drug also increases the plasma levels and cardiovascular effects of Adenosinergic agents (like Adenosine), which is the reason a mandatory 48-hour interruption of oral Dipyridamole is required before a pharmacological stress test.

Absorption and Specific Population Notes

Regulatory documents note that Gastric pH-Reducing Agents (e.g., Antacids) can reduce the systemic exposure of the immediate-release oral forms, necessitating separated administration times. Additionally, Dipyridamole may counteract the effect of Cholinesterase Inhibitors, which is a specific caution for patients with Myasthenia Gravis.

Mechanism of Action

How Perazodin Works

Perazodin (Dipyridamole) acts through a dual-pronged mechanism focused on modulating both extracellular and intracellular signaling pathways related to blood component activity and vascular tone.


Modulating Extracellular Purinergic Signals

This core mechanism involves the inhibition of the Equilibrative Nucleoside Transporter 1 (ENT1), a protein that normally clears Adenosine from the local tissue space. By blocking this transporter, the drug causes a sustained increase in the concentration of endogenous Adenosine, which then activates A2A receptors on both blood platelets and vascular smooth muscle cells. This key interaction initiates the cascade that results in the drug's characteristic physiological effects.


Amplifying Intracellular Inhibitory Messengers

The mechanism is amplified by the drug's role as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, particularly PDE3 within platelets. Since PDE is responsible for degrading the inhibitory messenger cyclic Adenosine Monophosphate (cAMP), its inhibition prevents the rapid breakdown of cAMP. This action reinforces the anti-clumping signal triggered by the Adenosine receptors, contributing to the amplification of platelet aggregation inhibition.


Resulting Physiological Consequences

The combined molecular action of enhancing Adenosine signaling and raising intracellular cAMP levels results in two primary physiological changes. The first is the inhibition of platelet aggregation and adhesion. The second is the reduction of vascular smooth muscle tone through A2A receptor activation, leading to the widening of blood vessels (vasodilation), which predominantly affects the coronary circulation.

Dosage and Administration Information

General Principles of Perazodin Use

Perazodin (Dipyridamole) is administered through two established routes: the oral route for long-term prophylaxis and the intravenous (IV) route for specialized cardiac diagnostic testing procedures. The specific dosage form and frequency are determined by the intended therapeutic context.

Dosing and Frequency Patterns

For chronic prophylaxis against blood clot formation, the immediate-release tablet is generally administered in ranges of 75 mg to 100 mg per dose, usually four times daily (q.i.d.). In contrast, the prolonged-release capsule formulation, which is often a fixed-dose combination, is administered twice daily (BID).

Administration Requirements and Timing

Oral administration of the immediate-release tablet is guided by timing relative to meals, and it is typically taken with water at least one hour before or two hours after meals. The prolonged-release capsule must be swallowed whole and must not be crushed, split, or chewed, as this compromises its intended release pattern.

Intravenous Procedural Use

Intravenous administration is reserved for clinical settings, such as myocardial perfusion imaging. This protocol involves a weight-based dose, such as 0.142 mg/kg/minute, to be infused steadily over a four-minute period. The injection solution must be diluted prior to infusion with specific solutions, such as sodium chloride or dextrose. Furthermore, oral Dipyridamole is discontinued at least 24 hours prior to undergoing this pharmacological stress test. Standard practice for a missed oral dose involves skipping the dose if it is near the time of the next scheduled dose to avoid double dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Stage Research: Exploration of Mechanism

Research explored the drug's interaction with specific signaling pathways. These studies evaluated the drug's effect on target cells in in vitro and animal models. Early research explored the drug's effect on pro-inflammatory cytokines in laboratory settings, but the full clinical implications of this area of investigation are still under review.


Phase III Clinical Trials: Assessing Outcomes in Clinical Trials

Studies examined the effects of the drug across several large-scale, randomized controlled trials (RCTs) in adults with Condition X.

Primary Outcomes Assessed

  • Pain Score Changes: Trials investigated whether the administration of the drug was associated with changes in patient-reported pain scores (e.g., using a 0–10 scale) compared to placebo. One key trial reported that participants receiving the drug had lower average pain scores at Week 12 than those in the placebo group; the differences were statistically significant.
  • Functional Capacity: Researchers evaluated whether changes occurred in physical function, as measured by standardized assessments (e.g., the A-B-C Index). Evidence remains limited regarding the consistency of these findings across all study populations.

Duration and Maintenance Studies

Trials exploring longer-term use (up to one year) have investigated the duration of the observed changes. These studies were designed to evaluate whether the initial differences in pain and function measurements persisted or diminished over time. Data from these extension studies are observational and therefore cannot establish causality for the long-term effects.


Adverse Events and Tolerability Data

Studies collected and analyzed data on adverse events (AEs) across all trial phases. The most frequently reported AEs included headache, nausea, and injection site reactions.

  • Serious Adverse Events: The overall incidence of serious AEs was comparable between the drug group and the placebo group in the short-term trials.
  • Special Populations: Research examined the use of the drug in specific patient populations, including those with mild-to-moderate liver impairment. The Prescribing Information details the study exclusion criteria and populations not included in the primary trials. It is not yet clear whether the drug is associated with similar outcomes in people with severe coexisting conditions.

Key Studies & References

  1. Efficacy and Safety of Perazodin in Chronic Condition X: A Phase 3 Randomized, Placebo-Controlled Trial
  2. Impact of Perazodin on Pro-inflammatory Cytokine Modulation in In Vitro Models

Frequently Asked Questions (FAQ)

Common questions about Perazodin (FAQ)

Q: Does Perazodin cause weight gain?

A: According to the official product information and safety data, weight gain is not listed as a frequent or common adverse reaction. The regulatory safety data focuses on other, more commonly reported side effects.


Q: Can Perazodin be used by people who are 65 years old or older?

A: Official prescribing information sometimes indicates that the maximum recommended oral daily dose is relevant for use in the elderly population. While use in older adults is possible, any specific cautions related to this age group are managed based on individual patient assessment.


Q: How often do the serious side effects of Perazodin happen?

A: Serious adverse events, such as myocardial infarction or stroke, are documented as rare to very rare events in clinical data. These specific severe reactions are primarily associated with the intravenous form of the medicine used during specialized diagnostic testing procedures.


Q: Is Perazodin safe to take during pregnancy, according to official warnings?

A: The oral formulation is not assigned a US FDA Pregnancy Category. Official warnings state that use during pregnancy should only be considered if the potential benefit justifies the potential risk, as safety has not been fully established.


Q: What information is available about Perazodin and use during breastfeeding?

A: Regulatory information indicates that the active ingredient is known to be excreted into human milk. Caution is recommended during this time, and use should only occur if a physician determines it is clearly needed.


Q: What type of monitoring (like blood tests) is sometimes done while on Perazodin?

A: While routine blood test monitoring for chronic oral use is not detailed, the label has reported elevated hepatic (liver) enzymes. Specific and continuous monitoring, such as an electrocardiogram (ECG) and blood pressure checks, is mandatory during the intravenous administration used for diagnostic procedures.


Q: Is it normal to feel a little dizzy when first starting Perazodin?

A: Yes, dizziness is listed as a Very Common adverse reaction in clinical data. This effect may be more noticeable when first starting the medicine but often lessens or may diminish with continued long-term use, according to official information.


Q: Is it normal to have vivid dreams or nightmares while taking Perazodin?

A: Vivid dreams or nightmares are not explicitly listed in the regulatory documents as a common or frequently reported psychiatric adverse reaction associated with the medicine. Official safety data often focuses on more common nervous system effects like dizziness and headache.


Q: Can Perazodin be used to treat panic attacks?

A: The official regulatory approval and documented general purpose of the medicine is for prophylaxis (prevention) against blood clot formation. It is classified as an antiplatelet agent and is not approved or primarily indicated for the treatment of panic attacks.


Q: Why do people say Perazodin is for [A condition] when the official use is [B condition]?

A: The medicine's officially approved use is for prophylactic anti-clotting action. However, research has also explored its effects in other areas, such as restless leg syndrome, or its use in cardiovascular diagnostic procedures. These investigational uses may lead to public discussion about non-labeled applications.


Q: Is Perazodin considered a controlled substance in the US or elsewhere?

A: Official US government sources do not classify the active ingredient in the medicine as a controlled substance under the Controlled Substances Act. It is categorized as a prescription-only medicine.


Q: How long does it typically take to start seeing the effects of Perazodin?

A: The medicine is generally prescribed for chronic, long-term use to maintain continuous blood flow effects. The half-life (the time it takes for half the dose to leave the body) is approximately 12 hours, meaning consistent, regular dosing is required to sustain its anti-clotting effect.


Q: Can Perazodin affect my sleep quality or patterns?

A: Official labeling does not list general sleep disturbance or insomnia as a common adverse reaction. However, rare nervous system effects reported in clinical data include somnolence (drowsiness).


Q: Are there any specific foods or drinks I should avoid while taking Perazodin?

A: For the oral product used chronically, a specific general food list is not provided. However, products containing caffeine or other methylxanthines must be avoided for at least 12 to 24 hours prior to a diagnostic procedure involving the intravenous medicine due to potential drug antagonism.


Q: How is Perazodin different from a traditional tranquilizer?

A: The medicine is officially classified as an antiplatelet agent and is used for prophylactic anti-clotting action. It is not categorized as a tranquilizer or medicine primarily intended to induce calm or reduce anxiety.


Q: How long does Perazodin stay in your system after stopping it?

A: The terminal half-life of the medicine in the body is approximately 12 hours. The medicine's physiological effect, the inhibition of blood clotting, typically ceases within about two days once treatment is fully discontinued.


Q: What is the typical timeframe for treatment with Perazodin?

A: This medicine is generally prescribed as a prophylactic agent for long-term use. It often requires chronic, continuous administration to sustain its effects against blood clot formation.


Q: Does Perazodin cause dependence or withdrawal symptoms?

A: The official regulatory documents do not describe the medicine as causing dependence or classic physical withdrawal symptoms. However, stopping the medicine may cause the return of the original underlying risk factors it was prescribed to address.


Q: Why is Perazodin sometimes prescribed with other medications?

A: The medicine is often prescribed alongside an anticoagulant or another antiplatelet agent because, in certain patient populations, combination therapy has been shown in studies to provide better protection against blood clot formation than using the medicine alone.


Q: Can Perazodin impact my ability to drive or operate machinery?

A: Official patient information indicates that driving or operating machinery may be avoided if you experience certain common side effects of the medicine, such as dizziness and headache.


Q: Does Perazodin lose its effect over time?

A: The medicine is designed for chronic, long-term prophylactic use. Studies have been conducted to evaluate whether its measured effects on blood flow and clotting persist over time.


Q: Can Perazodin be taken by teenagers?

A: Official labeling states that safety and effectiveness have not been established in the pediatric population below 12 years of age. However, professional information does sometimes mention an oral daily dose for adolescents.


Q: Does Perazodin cause high blood pressure?

A: The medicine is associated with vasodilation (blood vessel widening), which more commonly leads to low blood pressure (hypotension). High blood pressure (hypertension) has been reported in clinical data, but it is not listed among the most common adverse reactions.


Q: Why might a doctor switch a patient from another drug to Perazodin?

A: Clinical trials have examined the combination of the medicine with other antiplatelet agents, reporting that the combination provided a significantly greater reduction in the risk of stroke compared to using a single agent alone, which influences prescribing decisions.


Q: Can Perazodin interact with common over-the-counter pain relievers?

A: Yes, co-administration with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which are found in some over-the-counter pain relievers, increases the risk and severity of bleeding or hemorrhage due to additive effects on blood clotting.


Q: Does Perazodin interact with caffeine?

A: Caffeine can decrease the vasodilatory effects of the medicine. It is a mandatory requirement to avoid all products containing caffeine for at least 12 to 24 hours prior to undergoing a diagnostic procedure involving the intravenous medicine.


Q: How soon after stopping Perazodin can I take another type of medication?

A: A mandatory 48-hour interruption of the oral medicine is required before specific medical procedures, such as a pharmacological stress test using other adenosinergic agents. This is necessary due to the risk of increased cardiovascular side effects during the procedure.


Q: Can Perazodin cause temporary changes in vision?

A: Official clinical trial data documents that vision abnormalities (unspecified) are a reported uncommon adverse event. This means they occur in a small percentage of people.


Q: Does Perazodin have a sedative effect?

A: The medicine is not classified as a sedative. However, rare adverse reactions reported in nervous system disorders include somnolence (drowsiness).


Q: Is Perazodin a new drug or has it been around for a while?

A: The active ingredient in the medicine is considered an older pharmaceutical agent, having been first introduced for clinical use in 1959.


Q: What are the common reasons a doctor might prescribe Perazodin instead of another drug?

A: The medicine, often prescribed in combination with other antiplatelet agents, is chosen because clinical trials have shown that the combination provides a greater reduction in the risk of stroke than some single antiplatelet agents alone.


Q: What are the restrictions on using Perazodin for people with kidney disease?

A: Regulatory documents list a caution for use in patients with severe liver problems. However, they do not list a specific contraindication or special caution for individuals with kidney disease.


Q: Are people with a history of seizures allowed to take Perazodin?

A: A history of seizure disorder is listed as a relative contraindication for the use of the medicine during specific diagnostic procedures (like nuclear stress testing). This is due to the possible need for reversal agents that could worsen the condition.


Q: Does Perazodin have a black box warning?

A: Official US Prescribing Information does not display the unique formatting of a Boxed Warning (often called a 'black box warning') for the oral forms of the medicine.


Q: Can Perazodin interact with herbal supplements like St. John's Wort?

A: Regulatory documents do not specifically list St. John's Wort as an herb with a known interaction profile for the medicine.


Q: What is the risk of overdose with Perazodin?

A: The symptoms of taking more than the prescribed amount can include a faster heartbeat, chest pain, and feeling dizzy. The vasodilatory effects of the medicine in overdose may be managed with specific agents like aminophylline or caffeine in a supervised medical setting.


Q: Can Perazodin affect birth control pills?

A: Official regulatory documents do not list an interaction between the medicine and oral birth control pills.


Q: Does Perazodin interact negatively with alcohol?

A: For the extended-release combination product that includes aspirin, the consumption of alcohol is associated with an increased risk of serious stomach bleeding due to the aspirin component.

How should Perazodin be stored and disposed of?

Official Storage and Disposal Instructions

Perazodin (Dipyridamole) must be stored at controlled room temperature, typically between 20 C and 25 C (68 F to 77 F), and must not be stored above 25 C. The product requires protection and must be kept away from excess heat, moisture, and light. To maintain stability, the medication must remain in its original container, which must be kept tightly closed.

Specific in-use stability rules apply: certain opened oral formulations must be discarded within 30 days or six weeks.

It is mandatory to keep the medication out of the sight and reach of children.

Regarding disposal, Perazodin must not be discarded via household waste or flushed down the toilet. Unused or expired medication should be disposed of in accordance with local requirements, typically by returning it to a pharmacist or utilizing a designated medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perazodin found in:

A-Z Index: